Personalized medicine in acromegaly: The ACROFAST study.

Montserrat Marqués-Pamies Joan GilMiguel Sampedro-NuñezElena ValassiBetina BiagettiOlga Giménez-PalopMarta HernándezSilvia MartínezCristina CarratoRocío Villar-TaiboMarta Araujo-CastroConcepción BlancoInmaculada Simón-MuelaAndreu Simó-ServatGemma XifraFederico VázquezIsabel PavónJosé Antonio RosadoRogelio García-CentenoRoxana ZavalaFelicia Alexandra HanzuMireia MoraAnna AulinasNuria VilarrasaSoledad LibrizziMaría CalatayudPaz de MiguelCristina Alvarez-EscolaAntonio PicóIsabel SalinasCarmen Fajardo-MontañanaRosa CámaraIgnacio BernabéuMireia JordàSusan M WebbMónica MarazuelaManel Puig-Domingo

Published in: The Journal of clinical endocrinology and metabolism (2024)

Personalized medicine is feasible using a relatively simple protocol and allows a higher number of patients achieving control in a shorter period of time.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
patient reported outcomes